Atlantic Health Strategies logo
LinkedIn icon
Contact Us

Atlantic Health Strategies

X-twitter Linkedin
Atlantic Health Strategies Logo

Telehealth Methadone: What the 42 CFR Part 8 Final Rule and DEA’s 2026 Extension Actually Mean for OTP Operators

Table of Contents

Ready to See Results?

From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.

Contact Us

The short answer for operators

You cannot run a fully virtual methadone clinic in the United States. You can, however, initiate methadone via audio-visual telehealth inside a SAMHSA-certified Opioid Treatment Program (OTP), and DEA-registered practitioners can prescribe buprenorphine via telemedicine through at least December 31, 2026. That is the operator-relevant boundary line, and founders keep getting it wrong on both sides.

The rule that changed things is SAMHSA’s final rule revising 42 CFR Part 8, published February 2, 2024. The effective date was April 2, 2024, and the compliance date was October 2, 2024, so if you opened or acquired an OTP in Florida, Ohio, Texas, or anywhere else after last October, you are already inside this regulatory regime. On the DEA side, a fourth temporary extension is in effect January 1, 2026 through December 31, 2026, buying operators one more planning year before a permanent framework lands.

Everything below is what that means for a pro forma, a licensure package, and a survey window.

What SAMHSA actually changed (and what it did not)

The 2024 rewrite of 42 CFR Part 8 was the first substantive update to federal methadone regulation in over 20 years, and it was written to answer fentanyl. CDC recorded approximately 105,000 drug overdose deaths in 2023, with nearly 80,000, or about 76%, involving opioids. That is the pressure that produced the rule.

Here is what operators need to internalize:

For any telehealth encounter, SAMHSA requires the OTP to ensure the platform used is secure and HIPAA-compliant. That language matters when you are defending your telehealth workflow to a state opioid treatment authority.

The DEA piece, and why 2026 is a planning year, not a resting year

SAMHSA governs the OTP. The DEA governs the controlled-substance prescribing outside it. Founders confuse the two constantly.

On December 31, 2025, DEA, jointly with HHS, issued a fourth extension of telemedicine flexibilities for the prescribing of controlled medications through December 31, 2026. That covers buprenorphine (Schedule III) prescribed by qualified practitioners without a prior in-person visit. It does not turn methadone into a home-delivered product; methadone for OUD still moves through the OTP.

HHS framed the tradeoff in the December 2025 announcement. HHS Deputy Secretary Jim O’Neill called telehealth prescribing flexibilities “a lifeline for millions of Americans.” The DEA, in the same announcement, described the extension as a “bridge,” providing “additional time to finalize and implement effective regulations that balance access to care with the necessary safeguards against diversion”. Read that as a warning shot.

The January 2025 NPRM proposed a Special Registration for Telemedicine framework, and operators building buprenorphine telehealth models should be structuring their compliance program today around the assumption that a special registration, state-by-state telemedicine registration, and tighter diversion audits are the next step. If you are a private-equity buyer underwriting a buprenorphine telehealth platform in 2026, the diligence question is not “does the model work today?” It is “does the model survive the special registration rule and the SIU audit that follows?” Underwriting models I have reviewed assume $2,400 to $3,600 in annual net revenue per active buprenorphine telehealth patient. Cut that by 20% for a special-registration compliance overlay and re-run the exit multiple before you sign.

Where operators are getting hurt

A few patterns I keep seeing across OTP operators and buprenorphine telehealth platforms:

  1. Confusing SAMHSA’s rule with DEA’s rule. A COO in Georgia told me his team was building a “telehealth methadone induction protocol” and cited the DEA extension. Wrong statute. Methadone induction sits under 42 CFR Part 8, which requires audio-visual only and a HIPAA-compliant platform. If your policy manual cites the wrong regulator, your first mock survey will find it.
  2. Assuming federal preemption on mobile units. SAMHSA has stated that federal OTP regulations do not preempt separate state requirements, and some states restrict mobile units. Check your state opioid treatment authority before you buy the truck; a fitted mobile methadone unit runs roughly $350,000 to $500,000 before staffing.
  3. Underestimating the market growth. Per SAMHSA’s 2024 Federal Guidelines for Opioid Treatment Programs, in 2001 there were approximately 900 OTPs; by the end of 2023 that number grew to 2,115, and as of May 2024 SAMHSA had certified 2,151 OTPs across virtually all U.S. States and territories. That is more than a doubling of licensed OTP count in roughly two decades, and founders still write pro formas assuming a saturated market. In 2023, roughly 5.7 million people in the U.S. Had an opioid use disorder, and only about 18% (1.0 million people) received medication in the past year for their opioid use. In most of the states we work in, licensed capacity is nowhere near demand.
  4. Treating take-home policy as clinical, not operational. The 28-day take-home is a diversion-control problem, a storage problem, and a payer utilization-management problem before it is a clinical decision. Your SIU audit exposure changes the day you increase take-home volume.

None of this is theoretical. State methadone regulations in Florida, Tennessee, and West Virginia are being rewritten to match or narrow the federal rule right now, and your accreditation body will survey against whichever is stricter.

What to do before your next survey window

If you operate an OTP or you are acquiring one, four moves this quarter:

  1. Rewrite the telehealth SOP against the actual regulation. Cite 42 CFR Part 8 for methadone and buprenorphine screening inside the OTP. Cite the DEA extension for buprenorphine prescribing outside the OTP. Do not blend them.
  2. Update take-home decision documentation. The rule replaced rigid time-based criteria with practitioner judgment plus shared decision-making. Surveyors will ask how the clinician documented the reasoning. A blank field will become a finding.
  3. Confirm your state authority’s position. The federal effective date was April 2024. Your state opioid treatment authority may not have caught up, and the accreditation body will survey against both. Get the state’s written position in your policy binder.
  4. Diligence your payer contracts against the new workflow. Utilization management, timely filing, and audit provisions written before October 2024 may not contemplate audio-visual induction or extended take-homes. Managed care contracting cleanup is a same-quarter task, not a next-year task.

None of this is glamorous. All of it separates the OTPs that scale from the ones that spend Q3 fighting a corrective action plan.

Frequently asked questions

Can a patient start methadone treatment entirely through telehealth?

No. Under the 42 CFR Part 8 final rule, effective April 2, 2024 with a compliance date of October 2, 2024, a SAMHSA-certified OTP may conduct the initial screening examination for methadone via audio-visual telehealth (audio-only is not permitted for methadone), but the medication itself must still be dispensed through the OTP. SAMHSA has stated that the rule does not allow methadone to be prescribed for OUD outside of an OTP. There is no fully-remote methadone pathway.

Are DEA telehealth flexibilities for controlled substances still in effect in 2026?

Yes. On December 31, 2025, DEA and HHS issued a fourth temporary extension keeping the COVID-era telemedicine flexibilities in place from January 1, 2026 through December 31, 2026. DEA-registered practitioners may prescribe Schedule II-V controlled substances (including buprenorphine for OUD) via telemedicine without a prior in-person visit, subject to conditions. A permanent framework, including a proposed Special Registration for Telemedicine, is still under development.

How many take-home doses of methadone are now allowed?

The 2024 final rule made COVID-era flexibilities permanent, allowing up to 28 days of take-home methadone for stable patients. SAMHSA replaced the prior rigid time-in-treatment criteria with practitioner judgment and shared decision-making. States and accreditation bodies may impose additional documentation and diversion-control requirements, so OTP operators should update SOPs, storage protocols, and payer utilization-management workflows accordingly.

What is the biggest compliance risk for a new OTP building a telehealth workflow?

Conflating SAMHSA’s 42 CFR Part 8 rule with the DEA’s controlled-substance telemedicine extension. They govern different medications and different settings. Methadone induction sits under SAMHSA and must be audio-visual inside a certified OTP; buprenorphine prescribing outside an OTP sits under DEA’s extended flexibilities through December 31, 2026. Policy manuals that cite the wrong regulator produce findings on the first mock survey and jeopardize managed care contracts tied to accreditation status.

References

Request a Free Consultation

Scroll to Top